San Diego, United States
Neomorph, Inc. is at the forefront of breakthrough biotechnology, dedicated to advancing the science of targeted protein degradation to combat diseases once deemed untreatable. Positioned as a leader in developing molecular glue degraders, the company aims to transform therapeutic approaches for serious diseases by re-engineering protein surfaces to target and dismantle the very proteins driving these conditions.
Pioneering this field, Neomorph boasts the world's largest, proprietary target space of molecular glues, exploring numerous novel degrons and leveraging an expansive array of E3 ubiquitin ligases. Established in 2020, the company is headquartered in the United States and has caught the attention of significant backers, with prominent support from Deerfield Management Company.
The company's innovative platform holds promise for unlocking untapped therapeutic targets, making it a compelling prospect for investors in the biotech space, especially those intrigued by cutting-edge approaches to treating previously undruggable diseases.
